Monitoring of p53 autoantibodies in lung cancer during therapy: Relationship to response to treatment

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1359-1366

  Zalcman, Gérard ^a   Schlichtholz, Beata ^b   Trédaniel, Jean ^a   Urban, Thierry ^c   Lubin, Richard ^a,b   Dubois, Isabelle ^b   Milleron, Bernard ^d   Hirsch, Albert ^a   Soussi, Thierry ^b,e  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d HÔPITAL TENON   (France)

^e INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AUTOANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; DNA BINDING; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOPRECIPITATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONITORING; PRIORITY JOURNAL; REMISSION;

ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOANTIBODIES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETOPOSIDE; GENES, P53; HUMANS; LUNG NEOPLASMS; MONITORING, IMMUNOLOGIC; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031802031     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. De Leo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., and Old, L. J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA. 76: 2420-2424, 1979.
2. Kress, M., May, E., Cassingena, R., and May, P. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 serum. J. Virol., 31: 472-483, 1979.
3. Melero, J. A., Stitt, D. T., Mangel, W. F., and Carroll, R. B. Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in simian virus 40-infected and transformed cells. J. Virol., 93: 466-480, 1979.
4. Rotter, V., Witte, O. N., Coffman, R., and Baltimore, D. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, p50. J. Virol., 36: 547-555, 1980.
5. Crawford, L. V., Pim, D. C., and Bulbrook, R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30: 403-408, 1982.
6. Caron de Fromentel, C., May-Levin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K., and May, P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39: 185-189, 1987.
7. Ko, L. J., and Prives, C. p53: puzzle and paradigm. Genes Dev., 10: 1054-1072, 1996.
8. Midgley, C. A., and Lane, D. P. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene, 15: 1179-1189, 1997.
9. Ory, K., Legros, Y., Auguin, C., and Soussi, T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J., 13: 3496-3504, 1994.
10. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
11. Davidoff, A. M., Iglehart, J. D., and Marks, J. R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl. Acad. Sci. USA, 89: 3439-3442, 1992.
12. Schlichtholz, B., Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D., Calvo, F., and Soussi, T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res., 52: 6380-6384, 1992.
13. Winter, S. F., Minna, J. D., Johnson, B. E., Takahashi, T., Gazdar, A. F., and Carbone, D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res., 52: 4168-4174, 1992.
14. Hassapoglidoi, S., and Diamandis, E. P. Antibodies to the p53 tumor suppressor gene product quantified in cancer patients serum with a time-resolved immunofluorometry technique. Clin. Biochem., 25: 445-449, 1992.
15. Angelopoulou, K., Diamandis, E. P., Sutherland, D. J. A., Kellen, J. A., and Bunting, P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer, 58: 480-487, 1994.
16. Schlichtholz, B., Tredaniel, J., Lubin, R., Zalcman, G., Hirsch, A., and Soussi, T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer, 69: 809-816, 1994.
17. Lubin, R., Schlichtholz, B., Teillaud, J. L., Garay, E., Bussel, A., Wild, C., and Soussi. T. p53 antibodies in patients with various types of cancer: assay, identification and characterization. Clinical Cancer Res., 1: 1463-1469, 1995.
18. Wild, C. P., Ridanpaa, M., Anttila, S., Lubin, R., Soussi, T., Husgafvel-Fursiainen, K., and Vainino, H. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int. J. Cancer, 64: 176-181, 1995.
19. von Brevern, M. C., Hollstein, M. C., Cawley, H. M., De Benedetti, V. M. G., Bennett, W. P., Liang, L., He, A. G., Zhu, S. M., Tursz, T., Janin, N., and Trivers, G. E. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res., 56: 4917-4921, 1996.
20. Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Tredaniel, J., Hirsch, A., Caron de Fromentel, C., Preudhomme, C., Fenaux, P., Fournier, G., Mangin, P., Laurent-Puig, P., Pelletier, G., Schlumberger, M., Desgrandchamps, F., Leduc, A., Peyrat, J. P., Janin, N., Bressac, B., and Soussi, T. Analysis of p53 antibodies in patients with various cancers define B-Cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res., 53: 5872-5876, 1993.
21. Legros, Y., Lafon, C., and Soussi, T. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene, 9: 2071-2076, 1994.
22. Trivers, G. E., Cawley, H. L., Debenedetti, V. M. G., Hollstein, M., Marion, M. J., Bennett, W. P., Hoover, M. L., Prives, C. C., Tamburro, C. C., and Harris, C. C. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J. Natl. Cancer Inst., 87: 1400-1407, 1995.
23. Lubin, R., Zalcman, G., Bouchet, L., Trédaniel, J., Legros, Y., Cazals, D., Hirsh, A., and Soussi, T. Serum p53 antibodies as early markers of lung cancer. Nat. Med., 1: 701-702, 1995.
24. Hammel, P., Boissier, B., Chaumette, M. T., Piedbois, P., Rotman, N., Kouyoumdjian, J. C., Lubin, R., Delchier, J. C., and Soussi, T. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut, 40: 356-361, 1997.
25. Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., and Carbone, P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5: 649-655, 1982.
26. The World Health Organization histological typing of lung tumors. Am. J. Clin. Pathol., 77: 123-136, 1982.
27. Soussi, T. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol. Today, 17: 354-356, 1996.
28. Rainov, N. G., Dobberstein, K. U., Fittkau, M., Bahn, H., Holzausen, H. J., Gantchev, L., and Burkert, W. Absence of p53 antibodies in sera from glioma patients. Clin. Cancer Res., 1: 775-781, 1995.